Lucid Diagnostics and PAVmed Surge on U.S. Veterans Affairs Contract for EsoGuard DNA Test

Lucid Diagnostics and PAVmed have been awarded a contract by the US Department of Veterans Affairs for their EsoGuard DNA test, which detects oesophageal precancer. The contract expands access to oesophageal precancer testing across the VA healthcare system, which serves over 9 million veterans annually. EsoGuard's pre-negotiated pricing matches Medicare's payment rate, and the test has already generated $3.2 million in revenue for the 9 months ended September 30, 2025. Following the announcement, PAVmed surged 190% and Lucid Diagnostics jumped 28% in pre-market trading.